RT Generic
T1 Non-alcoholic fatty liver disease in patients with intestinal, pulmonary or skin diseases: Inflammatory cross-talk that needs a multidisciplinary approach
A1 Perez-Carreras, Mercedes
A1 Casis-Herce, Begona
A1 Rivera, Raquel
A1 Fernandez, Inmaculada
A1 Martinez-Montiel, Pilar
A1 Villena, Victoria
K1 Non-alcoholic fatty liver disease
K1 Liver fibrosis
K1 Psoriasis
K1 Obstructive sleep apnea
K1 Metabolic syndrome
K1 Inflammatory bowel disease
K1 Obstructive sleep-apnea
K1 Bowel-disease
K1 Metabolic syndrome
K1 Psoriasis
K1 Risk
K1 Steatohepatitis
K1 Pathogenesis
K1 Association
K1 Steatosis
K1 Severity
AB Non-alcoholic fatty liver disease (NAFLD) is currently considered the most common cause of liver disease. Its prevalence is increasing in parallel with the obesity and type 2 diabetes mellitus (DM2) epidemics in developed countries. Several recent studies have suggested that NAFLD may be the hepatic manifestation of a systemic inflammatory metabolic disease that also affects other organs, such as intestine, lungs, skin and vascular endothelium. It appears that local and systemic proinflammatory/anti-inflammatory cytokine imbalance, together with insulin resistance and changes in the intestinal microbiota, are pathogenic mechanisms shared by NAFLD and other comorbidities. NAFLD is more common in patients with extrahepatic diseases such as inflammatory bowel disease (IBD), obstructive syndrome apnea (OSA) and psoriasis than in the general population. Furthermore, there is evidence that this association has a negative impact on the severity of liver lesions. Specific risk characteristics for NAFLD have been identified in populations with IBD (i.e. age, obesity, DM2, previous bowel surgery, IBD evolution time, methotrexate treatment), OSA (i.e. obesity, DM2, OSA severity, increased transaminases) and psoriasis (i.e. age, metabolic factors, severe psoriasis, arthropathy, elevated transaminases, methotrexate treatment). These specific phenotypes might be used by gastroenterologists, pneumologists and dermatologists to create screening algorithms for NAFLD. Such algorithms should include non-invasive markers of fibrosis used in NAFLD to select subjects for referral to the hepatologist. Prospective, controlled studies in NAFLD patients with extrahepatic comorbidities are required to demonstrate a causal relationship and also that appropriate multidisciplinary management improves these patients' prognosis and survival.
PB Baishideng publishing group inc
SN 1007-9327
YR 2021
FD 2021-11-07
LK https://hdl.handle.net/10668/25474
UL https://hdl.handle.net/10668/25474
LA en
DS RISalud
RD Apr 6, 2025